Jul 2026· International Immunopharmacology· Vol 186, pp.
117123
· 0 citations· 25 references
Medicine
TL;DR
After combined treatment, uHCC patients were characterized by macrophages_FOLR2, CD8Teff, and LSEC, indicating a remodeling of the immune microenvironment.
Abstract
Background
The mechanisms underlying immune microenvironment remodeling remain unclear for patients with unresectable hepatocellular carcinoma (uHCC) undergoing transarterial chemoembolization (TACE) combined with tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs). This study aims to identify the key features that change following the combination therapy in patients with uHCC.
Methods
Single-cell transcriptomic profiling was conducted on uHCC samples from the control group, pre-treatment group, and post-treatment group. The Cancer Genome Atlas (TCGA) database was obtained for prognostic analysis. Enriched genes and pathways were identified, and the association and underlying mechanisms of the identified sub-cluster of cells were elucidated in relation to other cellular components.
Results
A total of 82,687 cells were obtained from seven patients with uHCC. In the pre-treatment group, the CancerCells_1 was associated with epithelial-mesenchymal transition, indicating a poor prognosis, as evidenced by data from 370 HCC patients in TCGA database. In the post-treatment group, a high proportion of macrophages_FOLR2 was observed corresponding to an elevated interferon response signature score and a diminished pro-angiogenic signature score. The exhaustion of CD8+ effector T cell (CD8Teff) was mitigated by downregulating the notable expression of BHLHE40 and CXCL13. Following treatment, there was an increase in liver sinusoidal endothelial cell (LSEC), while both angiogenesis and TGF-β pathway scores were reduced. Notable changes were observed in the interactions across different cells, particularly concerning the key signatures of LGALS9_HAVCR2, CSF1_CSF1R, and VEGFB_FLT1.
Conclusion
After combined treatment, uHCC patients were characterized by macrophages_FOLR2, CD8Teff, and LSEC, indicating a remodeling of the immune microenvironment.
A single-cell-resolved ferroptosis gene signature with strong prognostic and therapeutic implications for ESCC is presented, showing that knockdown of CDCA3 lead to the downregulation of ferroptosis inhibitor-related genes and upregulation of ferroptosis-promoting genes, thereby enhancing the sensitivity to RSL3-induce...
Qing Xu, Yu Ma, Xuanqi Huang et al.· Frontiers in Oncology· 0 citations
Single-cell transcriptomics of publicly available BLCA data identifies two transcriptionally distinct fibroblast states in adjacent tissue and supports an exploratory ligand–receptor interaction framework, warranting prospective validation with primary CAF populations and adequately powered multi-specimen cohorts.
Yan-Dong He, Wen-Long Lu, Guan-Qun Ju et al.· Frontiers in Cell and Develo...· 0 citations
Findings support the prognostic and therapeutic relevance of CR-related states in ccRCC and provide a framework for future experimental validation of chromatin-regulated tumor-immune interactions.
Lei Chen, Qing Wu, Cong Hong et al.· Biochemical and Biophysical...· 0 citations
This study identified a metabolically distinct malignant epithelial subpopulation enriched in MPLC tumors, characterized by upregulation of amino acid metabolism pathways and active MHC-II-mediated interactions with immunosuppressive CD4+ Treg cells and mast cells.
Yu-Li Zhao, Han-Yuan Zhao, Hui-Sheng Wu et al.· Frontiers in Immunology· 0 citations
The TME in residual ESCC after nICT is characterized and revealed an association between elevated TFAM expression in DCs and poor responsiveness to nICT, indicating the critical role of TFAM deficiency in DCs in activating anti-tumor immunity.
Linyan Chen, Tang Feng, Jian-Feng Zhou et al.· Cancer Research· 1 citation
A 25-gene prognostic model for LUSC is established and MBNL2 is identified as a novel correlate of poor pathological response to NACI, laying a foundation for future mechanistic investigation.
Hao Wu, Yang Cheng, Hong-Lin Yan et al.· Frontiers in Oncology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.